Massive Bio and CureMatch have established a collaboration to increase access to cancer clinical trials and precision oncology treatments. CureMatch’s decision support technology, which finds cancer treatments based on patients’ molecular tumor profiles, will be combined with Massive Bio’s AI platform, which will process patient data and connect them to clinical trials. The firms anticipate that by matching patients to studies regardless of their location, this collaboration will eliminate inequities in clinical trial enrolment. They also expect it will assist progress medication development by identifying more people to participate in clinical trials more swiftly. Massive Bio is not the only company to collaborate with Perthera.ai, Azra AI, and NeoGenomics to improve oncology clinical trial matching utilizing their AI-based platform. on the other hand.

To know more: About the original article click here.